1. Overview of the 2011 Work Programme Paul Griffiths Scientific committee meeting, Lisbon, November 2010

2. 2 Overview Three-year strategy (2010–2012) will be implemented through 3 annual work plans, 2011 WP is the 2’nd Heart of the agency work remains: State of the art review of the drug phenomenon Maintaining an up to date reference point on drugs Providing ongoing support to EU institution and Member states for monitoring and implementing the EU strategy and action plan 2011 WP Highlights Core activities Key indicators Monitoring responses Transversal analysis Supply reduction

3. 3 2011 focus Ensuring European system fits for the purpose & remaining responsive to developments Further dissemination of best practice Developing information sources in supply reduction Support the evaluation of the EU strategy and action plan Focus on polydrug use, combined analysis, policy-relevance analysis Dissemination and valorising EMCDDA findings 2011 WP Highlights Core activities Key indicators Monitoring responses Transversal analysis Supply reduction

4. 4 State of the art review Preparation of the Annual report package Efficient and methodologically sound data input, management and processing Top level strategic review of data collected and appropriateness of the instruments used Continue development of statistical bulletin Further technical development of FONTE and data warehouse 2011 WP Highlights Core activities Key indicators Monitoring responses Transversal analysis Supply reduction

5. 5 Remain methodologically sound Efficient collection and analysis of the KIs Maintaining and strengthen network Increase quality and comparability Better integration of youth survey (GPS) Final stage of rationalisation of TDI Broadening scope of PDU Update protocol of DRID Improve tools for mortality cohort data collection New data lab workshop (GPS, mortality registries) 2011 WP Highlights Core activities Key indicators Monitoring responses Transversal analysis Supply reduction

6. 6 Support to EC and rationalise data collection Support to the Council recommendation on prevention and reduction of health related harm Investigate and develop models for collecting data on: Opiates substitution treatment GPs Low-threshold agencies Cochrane systematic review on media campaigns Conceptual framework for coherent set of response indicators 2011 WP Highlights Core activities Key indicators Monitoring responses Transversal analysis Supply reduction

7. 7 Cross analysis and CUPs 2011 WP Highlights Core activities Key indicators Monitoring responses Transversal analysis Supply reduction Treatment coverage in subgroups of users Alcohol cannabis connections Polydrug use Drugs and driving CUP treatment: coherent supportive and scientifically sound approach for monitoring treatment in Europe CUP prison: scale up monitoring of prison setting CUP modelling: identify and support policy relevant analyses

8. 8 Development and adoption of indicators 2011 WP Highlights Core activities Key indicators Monitoring responses Transversal analysis Supply reduction Improving understanding of Europe’s specialised police units 3 expert groups (drug markets, drug- related crime, drug supply reduction) Second technical conference on DSSR

9. 9 Combine EWS and emerging trends 2011 WP New drugs Policy Good practice Main outputs Implement efficiently Council Decision (EWS) Assist in assessment of the Council decision Structured internet monitoring Further develop links with forensic/toxicology Trend-spotting- develop integrated approach for monitoring emerging trends Initial implementation of monitoring of misuse of medicinal products Multidisciplinary project on monitoring illicit drugs in waste water

10. 10 Improving Europe’s capacity to monitor and evaluate policies 2011 WP New drugs Policy Good practice Main outputs Review and develop framework for drug policy analysis Study on drug policy advocacy groups Contribute to the evaluation of the EU strategy and action plan And provide appropriate support to the commission in this area Model the impact on unemployment on drug issues

11. 11 Expend BPP and promote cooperation with scientific community 2011 WP New drugs Policy Good practice Main outputs Support EU project on standard and guidelines for interventions harm reduction and social rehabilitation Expend and continue promoting best practice in Europe Promote and facilitate EU research on drug issues Net work with scientific community and relevant organisations

12. 12 Annual report package EU drug strategy Scientific Monograph Insights Manuals Drug policy profiles Drugs in Focus Thematic papers Joint publications Online tools Articles Annual report Statistical bulletin Selected issues (treatment guidelines, cost of treatment, mortality) 2011 WP New drugs Policy Good practice Main outputs

13. 13 Annual report package EU drug strategy Scientific Monograph Insights Manuals Drug policy profiles Drugs in Focus Thematic papers Joint publications Online tools Articles Situation and responses review since 2005 2011 WP New drugs Policy Good practice Main outputs EMCDDA public website Best practice portal ELDD Country intervention profiles

14. 14 Annual report package EU drug strategy Scientific Monograph Insights Manuals Drug policy profiles Drugs in Focus Thematic papers Joint publications Online tools Articles New groups of psychoactive substances 2011 WP New drugs Policy Good practice Main outputs European ecstasy market (Europol) Guidance on prevention of infections among IDus (ECDC

15. 15 Annual report package EU drug strategy Scientific Monograph Insights Manuals Drug policy profiles Drugs in Focus Thematic papers Joint publications Online tools Articles 2011 WP New drugs Policy Good practice Main outputs Emerging drug trends case study Drug couriers New methods for cross analysis of prevention trials Drug user perspective in quitting drug use, etc…. Cannabis market and production Heroin-assisted treatment Models of dependency and compulsive behaviour

16. 16 Annual report package EU drug strategy Scientific Monograph Insights Manuals Drug policy profiles Drugs in Focus Thematic papers Joint publications Online tools Articles 2011 WP New drugs Policy Good practice Main outputs DRID protocol Mortality cohort protocol Guidelines for evaluation of national drug strategies Responding to psychoactive substances Minimum quality standard of interventions Drug-related research Khat

17. 17 Annual report package EU drug strategy Scientific Monograph Insights Manuals Drug policy profiles Drugs in Focus Thematic papers Joint publications Online tools Articles 2011 WP New drugs Policy Good practice Main outputs New series of national drug policy profiles

18. Questions and discussion